Honegger A M, Schmidt A, Ullrich A, Schlessinger J
Rorer Biotechnology, Inc., King of Prussia, Pennsylvania 19406.
Mol Cell Biol. 1990 Aug;10(8):4035-44. doi: 10.1128/mcb.10.8.4035-4044.1990.
In response to epidermal growth factor (EGF) stimulation, the intrinsic protein tyrosine kinase of EGF receptor is activated, leading to tyrosine phosphorylation of several cellular substrate proteins, including the EGF receptor molecule itself. To test the mechanism of EGF receptor autophosphorylation in living cells, we established transfected cell lines coexpressing a kinase-negative point mutant of EGF receptor (K721A) with an active EGF receptor mutant lacking 63 amino acids from its carboxy terminus. The addition of EGF to these cells caused tyrosine phosphorylation of the kinase-negative mutant by the active receptor molecule, demonstrating EGF receptor cross-phosphorylation in living cells. After internalization the kinase-negative mutant and CD63 have separate trafficking pathways. This limits their association and the extent of cross-phosphorylation of K721A by CD63. The coexpression of the kinase-negative mutant together with active EGF receptors in the same cells suppressed the mitogenic response toward EGF as compared with that in cells that express active receptors alone. The presence of the kinase-negative mutant functions as a negative dominant mutation suppressing the response of active EGF receptors, probably by interfering with EGF-induced signal transduction. It appears, therefore, that crucial events of signal transduction occur before K721A and active EGF receptors are separated by their different endocytic itineraries.
在对表皮生长因子(EGF)刺激的反应中,EGF受体的内在蛋白酪氨酸激酶被激活,导致几种细胞底物蛋白发生酪氨酸磷酸化,包括EGF受体分子自身。为了测试活细胞中EGF受体自磷酸化的机制,我们建立了共表达EGF受体激酶阴性点突变体(K721A)和一个从其羧基末端缺失63个氨基酸的活性EGF受体突变体的转染细胞系。向这些细胞中添加EGF导致活性受体分子使激酶阴性突变体发生酪氨酸磷酸化,证明了活细胞中EGF受体的交叉磷酸化。内化后,激酶阴性突变体和CD63有不同的运输途径。这限制了它们的结合以及CD63对K721A的交叉磷酸化程度。与仅表达活性受体的细胞相比,在同一细胞中共表达激酶阴性突变体和活性EGF受体抑制了对EGF的促有丝分裂反应。激酶阴性突变体的存在起到负显性突变的作用,抑制活性EGF受体的反应,可能是通过干扰EGF诱导的信号转导。因此,似乎信号转导的关键事件发生在K721A和活性EGF受体通过其不同的内吞途径分离之前。